Tag results:

triple negative breast cancer

H3K27me3 Conditions Chemotolerance in Triple-Negative Breast Cancer

[Nature Genetics] By monitoring epigenomes, transcriptomes and lineages with single-cell resolution, scientists showed that the repressive histone mark trimethylation of histone H3 at lysine 27 (H3K27me3) regulated cell fate at the onset of chemotherapy.

Progesterone Activates GPR126 to Promote Breast Cancer Development via the Gi Pathway

[Proceedings of the National Academy of Sciences of the United States of America] Scientists identified a membrane receptor for progesterone/17-hydroxyprogesterone and delineated the mechanisms by which GPR126 participated in potential tumor progression in TNBC.

Modified Bovine Milk Exosomes for Doxorubicin Delivery to Triple-Negative Breast Cancer Cells

[ACS Applied Bio Materials] Scientists described the use of two chemical modifications, incorporating a neuropilin receptor agonist peptide and a hypoxia-responsive lipid for targeting and release of an encapsulated drug from bovine milk exosomes toTNBC cells.

A Positive Feedback Loop: RAD18-YAP-TGF-β between Triple-Negative Breast Cancer and Macrophages Regulates Cancer Stemness and Progression

[Cell Death Discovery] TGF-β from tumor-associated macrophages activated RAD18 in triple-negative breast cancer to enhance tumor stemness, forming a positive feedback loop. Inhibition of YAP or TGF-β broke this loop and suppressed cancer stemness and proliferation.

The Natural Antisense Transcript HAS2-AS1 Regulates Breast Cancer Cells Aggressiveness Independently from Hyaluronan Metabolism

[Matrix Biology] Scientists reported that estrogen receptor (ER)-positive breast cancers had lower hyaluronan synthase 2 antisense RNA 1 (HAS2-AS1) expression compared to ER-negative tumors. Moreover, the survival of patients with ER-negative tumors was higher when the expression of HAS2-AS1 was elevated.

FER Regulates Endosomal Recycling and Is a Predictor for Adjuvant Taxane Benefit in Breast Cancer

[Cell Reports] The authors showed that high feline sarcoma-related non-receptor tyrosine kinase (FER) levels were also associated with improved outcomes after adjuvant taxane-based combination chemotherapy in high-risk, HER2-negative patients.